{
    "nctId": "NCT00751101",
    "briefTitle": "Nicotine Patches in Reducing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine For Metastatic Breast Cancer",
    "officialTitle": "Pilot Study of Nicotine Patches to Reduce Hand-Foot Syndrome Associated With Capecitabine Chemotherapy in Patients With Metastatic Breast Cancer",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer, Chemotherapeutic Agent Toxicity, Palmar-plantar Erythrodysesthesia",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 24,
    "primaryOutcomeMeasure": "Number of Patients Who Developed Hand-foot Syndrome (HFS) by Toxicity Grade",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Diagnosis of breast cancer\n\n  * Metastatic disease\n* Scheduled to begin treatment with capecitabine at the University of California, San Francisco (UCSF) Cancer Center, San Francisco General Hospital, or Cornell Medical Center\n* No concurrent hand-foot syndrome (HFS) due to other medications\n\n  * Prior HFS due to other medications allowed provided that the symptoms have been completely resolved for \u2265 4 weeks prior to study entry\n* Hormone receptor status not specified\n\nPATIENT CHARACTERISTICS:\n\n* Menopausal status not specified\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception during and for 6 months after completion of study therapy\n* Able to participate in study procedures and quality-of-life evaluations and willing to comply with study requirements\n* Non-English speaking patients are allowed provided they demonstrate adequate understanding of the study rationale and procedures and can give voluntary consent with the aid of a translator\n* No clinically significant cardiac or peripheral vascular disease or symptom, including any of the following:\n\n  * History of myocardial infarction\n  * Congestive heart failure\n  * Cardiac arrhythmias (including atrial fibrillation)\n  * Cardiac or vascular bypass\n  * Uncontrolled hypertension\n  * Unstable angina\n  * Undiagnosed arrhythmias or claudication\n* No Alzheimer disease, Parkinson disease, or active psychiatric disease\n* Not currently smoking\n\n  * Patients who are former smokers must have stopped smoking \u2265 6 months prior to study entry\n* No known hypersensitivity to nicotine patches\n\nPRIOR CONCURRENT THERAPY:\n\n* At least 6 months since prior and no other concurrent nicotine patches\n* Prior chemotherapy allowed, except capecitabine for treatment of metastatic disease\n* Concurrent other symptomatic treatment for hand-foot syndrome (HFS) (e.g., usual skin care, topical moisturizers, ice packs, pain medications) allowed\n* No concurrent pyridoxine",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}